MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
Bian Y, Han J, Kannabiran V, Mohan S, Cheng H, Friedman J, Zhang L, VanWaes C, Chen Z. MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer. International Journal Of Biological Sciences 2015, 11: 411-422. PMID: 25798061, PMCID: PMC4366640, DOI: 10.7150/ijbs.10745.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBlotting, WesternCasein Kinase IICell Line, TumorDiphenylamineFemaleFlow CytometryHead and Neck NeoplasmsHumansJNK Mitogen-Activated Protein KinasesMiceMice, Inbred BALB CMice, SCIDNaphthyridinesNF-kappa BPhenazinesProto-Oncogene Proteins c-fosTumor Suppressor Protein p53Xenograft Model Antitumor AssaysConceptsAnti-tumor activityMEK inhibitor PD-0325901PD-901CK2 inhibitor CXModest anti-tumor activityNeck squamous cell carcinomaPD-0325901Cell linesSignificant anti-tumor effectHuman HNSCC cell linesUM-SCC cell linesP-AKT T308Squamous cell carcinomaIL-8 activityFurther clinical investigationAnti-tumor effectsHNSCC cell linesDNA flow cytometryAP-1 pathwayDrug resistance mechanismsExhibit anti-tumor activityResistance mechanismsUM-SCC1Cell carcinomaNeck cancer